SUrrogate markers for Micro- and Macro-vascular hard endpoints for Innovative diabetes Tools
I'm a title. Click here to edit me
Press Release
Announcing SUMMIT breaking news
IMI Diabetes Platform signs a Memorandum of Understanding
IMIDIA, DIRECT and SUMMIT take a step forward to further strengthen European diabetes research with the signature of their Memorandum of Understanding and with that increasing the interactions between the three IMI diabetes projects.
Navigation
MISSION
To DISCOVER, DEVELOP and QUALIFY potential MARKERS that empower:
-
the identification of patients at high risk of diabetes complications
-
the monitoring of the complications' progression and patients‘ response to therapy
To use the discovered markers as SURROGATE ENDPOINTS in clinical trials.
Thereby, SHORTEN the long lasting CLINICAL TRIALS to bring about EARLIER availability of NEW THERAPY to diabetic patients.
Related Sites
